MKVentures Capital Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 12, 2025, 11:10 pm

Quick Insight

MKVentures Capital Ltd, with a share price of 1,447 and a market cap of 556 Cr., shows a high P/E ratio of 65.6, indicating investors are willing to pay a premium for future growth potential. The company's ROE stands at 9.56%, while ROCE is robust at 16.6%, reflecting efficient capital utilization. With an OPM of 91.71%, MKVentures demonstrates strong operational efficiency. The firm's healthy reserves of 98.77 Cr. and zero borrowings signify a strong financial position. However, the high P/BV ratio of 5.09x suggests the stock may be overvalued. Investors should carefully consider these metrics before making investment decisions in MKVentures Capital Ltd.

Competitors of MKVentures Capital Ltd

All Competitor Stocks of MKVentures Capital Ltd

Quarterly Result

Last Updated: August 21, 2025, 1:47 pm

Below is a detailed analysis of the quarterly data for MKVentures Capital Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 6.03 Cr.. The value appears strong and on an upward trend. It has increased from 2.88 Cr. (Mar 2025) to 6.03 Cr., marking an increase of 3.15 Cr..
• For Expenses, as of Jun 2025, the value is 0.50 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.53 Cr. (Mar 2025) to 0.50 Cr., marking a decrease of 9.03 Cr..
• For Operating Profit, as of Jun 2025, the value is 5.53 Cr.. The value appears strong and on an upward trend. It has increased from -6.65 Cr. (Mar 2025) to 5.53 Cr., marking an increase of 12.18 Cr..
• For OPM %, as of Jun 2025, the value is 91.71%. The value appears strong and on an upward trend. It has increased from -230.90% (Mar 2025) to 91.71%, marking an increase of 322.61%.
• For Other Income, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.53 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.07 Cr..
• For Interest, as of Jun 2025, the value is 0.42 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.57 Cr. (Mar 2025) to 0.42 Cr., marking a decrease of 0.15 Cr..
• For Depreciation, as of Jun 2025, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.09 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.03 Cr..
• For Profit before tax, as of Jun 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from -6.78 Cr. (Mar 2025) to 5.51 Cr., marking an increase of 12.29 Cr..
• For Tax %, as of Jun 2025, the value is 22.87%. The value appears to be increasing, which may not be favorable. It has increased from -21.09% (Mar 2025) to 22.87%, marking an increase of 43.96%.
• For Net Profit, as of Jun 2025, the value is 4.24 Cr.. The value appears strong and on an upward trend. It has increased from -5.35 Cr. (Mar 2025) to 4.24 Cr., marking an increase of 9.59 Cr..
• For EPS in Rs, as of Jun 2025, the value is 11.03. The value appears strong and on an upward trend. It has increased from -13.92 (Mar 2025) to 11.03, marking an increase of 24.95.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 12:51 pm

Growth

Last Updated: September 5, 2025, 3:55 pm

Cash Flow

No data available for the No. of Shareholders chart.

Key Financial Ratios

After reviewing the key financial ratios for MKVentures Capital Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 55.46 (Mar 24) to 24.69, marking a decrease of 30.77.
• For Diluted EPS (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 55.46 (Mar 24) to 24.69, marking a decrease of 30.77.
• For Cash EPS (Rs.), as of Mar 25, the value is 25.67. This value is within the healthy range. It has decreased from 55.29 (Mar 24) to 25.67, marking a decrease of 29.62.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 267.70. It has increased from 243.95 (Mar 24) to 267.70, marking an increase of 23.75.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 267.70. It has increased from 243.95 (Mar 24) to 267.70, marking an increase of 23.75.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 65.57. It has decreased from 101.54 (Mar 24) to 65.57, marking a decrease of 35.97.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 43.50. This value is within the healthy range. It has decreased from 100.71 (Mar 24) to 43.50, marking a decrease of 57.21.
• For PBIT / Share (Rs.), as of Mar 25, the value is 42.52. This value is within the healthy range. It has decreased from 100.50 (Mar 24) to 42.52, marking a decrease of 57.98.
• For PBT / Share (Rs.), as of Mar 25, the value is 34.15. This value is within the healthy range. It has decreased from 75.05 (Mar 24) to 34.15, marking a decrease of 40.90.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 55.09 (Mar 24) to 24.69, marking a decrease of 30.40.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has decreased from 55.09 (Mar 24) to 24.69, marking a decrease of 30.40.
• For PBDIT Margin (%), as of Mar 25, the value is 66.34. This value is within the healthy range. It has decreased from 99.18 (Mar 24) to 66.34, marking a decrease of 32.84.
• For PBIT Margin (%), as of Mar 25, the value is 64.85. This value exceeds the healthy maximum of 20. It has decreased from 98.98 (Mar 24) to 64.85, marking a decrease of 34.13.
• For PBT Margin (%), as of Mar 25, the value is 52.08. This value is within the healthy range. It has decreased from 73.91 (Mar 24) to 52.08, marking a decrease of 21.83.
• For Net Profit Margin (%), as of Mar 25, the value is 37.65. This value exceeds the healthy maximum of 10. It has decreased from 54.25 (Mar 24) to 37.65, marking a decrease of 16.60.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 37.65. This value exceeds the healthy maximum of 20. It has decreased from 54.25 (Mar 24) to 37.65, marking a decrease of 16.60.
• For Return on Networth / Equity (%), as of Mar 25, the value is 9.22. This value is below the healthy minimum of 15. It has decreased from 22.58 (Mar 24) to 9.22, marking a decrease of 13.36.
• For Return on Capital Employeed (%), as of Mar 25, the value is 13.38. This value is within the healthy range. It has decreased from 40.69 (Mar 24) to 13.38, marking a decrease of 27.31.
• For Return On Assets (%), as of Mar 25, the value is 6.74. This value is within the healthy range. It has decreased from 16.21 (Mar 24) to 6.74, marking a decrease of 9.47.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.18. It has increased from 0.17 (Mar 24) to 0.18, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 6.21. This value exceeds the healthy maximum of 3. It has increased from 3.22 (Mar 24) to 6.21, marking an increase of 2.99.
• For Quick Ratio (X), as of Mar 25, the value is 6.21. This value exceeds the healthy maximum of 2. It has increased from 3.22 (Mar 24) to 6.21, marking an increase of 2.99.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 5.19. This value is within the healthy range. It has increased from 3.96 (Mar 24) to 5.19, marking an increase of 1.23.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.95. This value is within the healthy range. It has increased from 3.16 (Mar 24) to 3.95, marking an increase of 0.79.
• For Enterprise Value (Cr.), as of Mar 25, the value is 518.00. It has decreased from 588.14 (Mar 24) to 518.00, marking a decrease of 70.14.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 20.55. This value exceeds the healthy maximum of 3. It has increased from 15.07 (Mar 24) to 20.55, marking an increase of 5.48.
• For EV / EBITDA (X), as of Mar 25, the value is 30.98. This value exceeds the healthy maximum of 15. It has increased from 15.20 (Mar 24) to 30.98, marking an increase of 15.78.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 20.78. This value exceeds the healthy maximum of 3. It has increased from 15.91 (Mar 24) to 20.78, marking an increase of 4.87.
• For Price / BV (X), as of Mar 25, the value is 5.09. This value exceeds the healthy maximum of 3. It has decreased from 6.62 (Mar 24) to 5.09, marking a decrease of 1.53.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 20.78. This value exceeds the healthy maximum of 3. It has increased from 15.91 (Mar 24) to 20.78, marking an increase of 4.87.
• For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness